{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,15]],"date-time":"2026-10-15T23:27:05Z","timestamp":1792106825430,"version":"4.4.0"},"reference-count":22,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2021,3,16]],"date-time":"2021-03-16T00:00:00Z","timestamp":1615852800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["81571603 81601833 81701615"],"award-info":[{"award-number":["81571603 81601833 81701615"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Pharmacol."],"abstract":"<jats:p><jats:bold>Objective:<\/jats:bold> To evaluate the efficacy of tocilizumab (TCZ) in adult patients with refractory immune-mediated necrotizing myopathies (IMNMs) and investigate possible predictive biomarkers of the response to treatment with TCZ.<\/jats:p><jats:p><jats:bold>Methods:<\/jats:bold> Patients with refractory IMNM were enrolled in this open-label pilot observational study and received intravenous TCZ treatment. The clinical response was assessed after 6 months of TCZ treatment according to the 2016 American College of Rheumatology\u2013European League Against Rheumatism (ACR\u2013EULAR) response criteria for adult dermatomyositis and polymyositis. Muscle biopsies were performed to investigate muscle fiber regeneration by immunohistochemical staining of CD56. Serum levels of interleukin (IL)-6 were measured using a multiplex bead-based flow fluorescent immunoassay. The levels of muscle IL-6 mRNA were detected by real-time polymerase chain reaction.<\/jats:p><jats:p><jats:bold>Results:<\/jats:bold> A total of 11 patients with refractory IMNM were enrolled in the study, including 3 anti-3-hydroxy-3-methylglutaryl-CoA reductase- and 8 anti-signal recognition particle-positive patients. Seven (63.6%) of these patients achieved clinically significant responses according to the 2016 ACR\u2013EULAR myositis response criteria. Responders had higher baseline serum IL-6 and muscle IL-6 mRNA levels and percentage of CD56-positive muscle fibers than non-responders. Baseline serum IL-6 levels and the percentage of CD56-positive muscle fibers were positively correlated with total improvement score after 6 months of TCZ treatment. Furthermore, muscle fiber necrosis and muscle fiber size variation decreased in repeated muscle biopsies in five responders.<\/jats:p><jats:p><jats:bold>Conclusion:<\/jats:bold> Patients with refractory IMNM may respond to TCZ. Baseline serum IL-6 and muscle IL-6 mRNA levels and the percentage of CD56-positive muscle fibers may predict the response to TCZ treatment in these patients.<\/jats:p>","DOI":"10.3389\/fphar.2021.635654","type":"journal-article","created":{"date-parts":[[2021,3,16]],"date-time":"2021-03-16T06:37:44Z","timestamp":1615876664000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":32,"title":["The Efficacy of Tocilizumab in the Treatment of Patients with Refractory Immune-Mediated Necrotizing Myopathies: An Open-Label Pilot Study"],"prefix":"10.3389","volume":"12","author":[{"given":"Sizhao","family":"Li","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wenli","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wei","family":"Jiang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Linrong","family":"He","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qinglin","family":"Peng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Guochun","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xin","family":"Lu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2021,3,16]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"792","DOI":"10.1136\/annrheumdis-2017-211400","article-title":"2016 American College of Rheumatology\/European league against rheumatism criteria for minimal, moderate, and major clinical response in adult dermatomyositis and polymyositis: an international myositis assessment and clinical studies group\/paediatric rheumatology international trials organisation collaborative initiative","volume":"76","author":"Aggarwal","year":"2017","journal-title":"Ann. Rheum. Dis."},{"key":"B2","doi-asserted-by":"publisher","first-page":"e507","DOI":"10.1212\/WNL.0000000000004923","article-title":"Necrosis in anti-SRP+ and anti-HMGCR+myopathies: role of autoantibodies and complement","volume":"90","author":"Allenbach","year":"","journal-title":"Neurology"},{"key":"B3","doi-asserted-by":"publisher","first-page":"87","DOI":"10.1016\/j.nmd.2017.09.016","article-title":"224th ENMC international workshop: clinico-sero-pathological classification of immune-mediated necrotizing myopathies Zandvoort, The Netherlands, 14-16 october 2016","volume":"28","author":"Allenbach","year":"","journal-title":"Neuromuscul. Disord."},{"key":"B4","doi-asserted-by":"publisher","first-page":"538","DOI":"10.1002\/ana.24902","article-title":"Pathogenic role of anti-signal recognition protein and anti-3-Hydroxy-3-methylglutaryl-CoA reductase antibodies in necrotizing myopathies: myofiber atrophy and impairment of muscle regeneration in necrotizing autoimmune myopathies","volume":"81","author":"Arouche-Delaperche","year":"2017","journal-title":"Ann. Neurol."},{"key":"B5","doi-asserted-by":"publisher","first-page":"2013","DOI":"10.1091\/mbc.e03-08-0585","article-title":"p38 MAPK-induced nuclear factor-kappaB activity is required for skeletal muscle differentiation: role of interleukin-6","volume":"15","author":"Baeza-Raja","year":"2004","journal-title":"Mol. Biol. Cell"},{"key":"B6","doi-asserted-by":"publisher","first-page":"361","DOI":"10.1016\/j.jbspin.2015.03.016","article-title":"Antisynthetase syndrome treated with tocilizumab","volume":"83","author":"Beaumel","year":"2016","journal-title":"Jt. Bone Spine"},{"key":"B7","doi-asserted-by":"publisher","first-page":"393","DOI":"10.1056\/NEJMc1506827","article-title":"Inflammatory muscle diseases","volume":"373","author":"Dalakas","year":"2015","journal-title":"N. Engl. J. Med."},{"key":"B8","doi-asserted-by":"publisher","first-page":"3170","DOI":"10.1016\/j.bbagen.2014.01.014","article-title":"Anti-interleukin-6 receptor antibody (MR16-1) promotes muscle regeneration via modulation of gene expressions in infiltrated macrophages","volume":"1840","author":"Fujita","year":"2014","journal-title":"Biochim. Biophys. Acta (BBA)-Gen. Subjects"},{"key":"B9","doi-asserted-by":"publisher","first-page":"e0141616","DOI":"10.1371\/journal.pone.0141616","article-title":"Clinical characteristics of anti-3-hydroxy-3-methylglutaryl coenzyme A reductase antibodies in Chinese patients with idiopathic inflammatory myopathies","volume":"10","author":"Ge","year":"2015","journal-title":"PLoS One"},{"key":"B10","doi-asserted-by":"publisher","first-page":"1624","DOI":"10.1038\/s41467-017-01866-w","article-title":"MyD88 promotes myoblast fusion in a cell-autonomous manner","volume":"8","author":"Hindi","year":"2017","journal-title":"Nat. Commun."},{"key":"B11","doi-asserted-by":"publisher","first-page":"1907","DOI":"10.1093\/rheumatology\/keu234","article-title":"A case of overlap syndrome successfully treated with tocilizumab: a hopeful treatment strategy for refractory dermatomyositis?","volume":"53","author":"Kondo","year":"2014","journal-title":"Rheumatology"},{"key":"B12","doi-asserted-by":"publisher","first-page":"1943","DOI":"10.1096\/fj.10-176487","article-title":"Sequenced response of extracellular matrix deadhesion and fibrotic regulators after muscle damage is involved in protection against future injury in human skeletal muscle","volume":"25","author":"Mackey","year":"2011","journal-title":"Faseb J."},{"key":"B13","doi-asserted-by":"publisher","first-page":"4131","DOI":"10.1111\/febs.1233810.1111\/febs.12454","article-title":"Interleukin-6 myokine signaling in skeletal muscle: a double-edged sword?","volume":"280","author":"Munoz-Canoves","year":"2013","journal-title":"FEBS J."},{"key":"B14","doi-asserted-by":"publisher","first-page":"1344","DOI":"10.1093\/rheumatology\/ker152","article-title":"Therapeutic effect of tocilizumab on two patients with polymyositis","volume":"50","author":"Narazaki","year":"2011","journal-title":"Rheumatology"},{"key":"B15","doi-asserted-by":"publisher","first-page":"206026","DOI":"10.1155\/2014\/206026","article-title":"IL-6 impairs myogenic differentiation by downmodulation of p90RSK\/eEF2 and mTOR\/p70S6K axes, without affecting AKT activity","volume":"2014","author":"Pelosi","year":"2014","journal-title":"Biomed. Res. Int."},{"key":"B16","doi-asserted-by":"publisher","first-page":"263","DOI":"10.1002\/acr.22920","article-title":"Longitudinal course of disease in a large cohort of myositis patients with autoantibodies recognizing the signal recognition particle","volume":"69","author":"Pinal-Fernandez","year":"2017","journal-title":"Arthritis Care Res."},{"key":"B17","doi-asserted-by":"publisher","first-page":"33","DOI":"10.1016\/j.cmet.2007.11.011","article-title":"Interleukin-6 is an essential regulator of satellite cell-mediated skeletal muscle hypertrophy","volume":"7","author":"Serrano","year":"2008","journal-title":"Cell Metab."},{"key":"B18","doi-asserted-by":"publisher","first-page":"987","DOI":"10.1016\/s0140-6736(08)60453-5","article-title":"Effect of interleukin-6 receptor inhibition with tocilizumab in patients with rheumatoid arthritis (OPTION study): a double-blind, placebo-controlled, randomised trial","volume":"371","author":"Smolen","year":"2008","journal-title":"Lancet"},{"key":"B19","doi-asserted-by":"publisher","first-page":"317","DOI":"10.1056\/NEJMoa1613849","article-title":"Trial of tocilizumab in giant-cell arteritis","volume":"377","author":"Stone","year":"2017","journal-title":"N. Engl. J. Med."},{"key":"B20","doi-asserted-by":"publisher","first-page":"787","DOI":"10.1093\/rheumatology\/kew470","article-title":"More severe disease and slower recovery in younger patients with anti-3-hydroxy-3-methylglutaryl-coenzyme A reductase-associated autoimmune myopathy","volume":"56","author":"Tiniakou","year":"2017","journal-title":"Rheumatology"},{"key":"B21","doi-asserted-by":"publisher","first-page":"55","DOI":"10.1136\/annrheumdis-2017-211751","article-title":"Abatacept in the treatment of adult dermatomyositis and polymyositis: a randomised, phase IIb treatment delayed-start trial","volume":"77","author":"Tjarnlund","year":"2018","journal-title":"Ann. Rheum. Dis."},{"key":"B22","doi-asserted-by":"publisher","first-page":"23","DOI":"10.1186\/s13395-017-0140-z","article-title":"Treatment with the anti-IL-6 receptor antibody attenuates muscular dystrophy via promoting skeletal muscle regeneration in dystrophin-\/utrophin-deficient mice","volume":"7","author":"Wada","year":"2017","journal-title":"Skeletal Muscle"}],"container-title":["Frontiers in Pharmacology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fphar.2021.635654\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,3,16]],"date-time":"2021-03-16T06:37:46Z","timestamp":1615876666000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fphar.2021.635654\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,3,16]]},"references-count":22,"alternative-id":["10.3389\/fphar.2021.635654"],"URL":"https:\/\/doi.org\/10.3389\/fphar.2021.635654","relation":{},"ISSN":["1663-9812"],"issn-type":[{"value":"1663-9812","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,3,16]]},"article-number":"635654"}}